4.7 Article

A Case of Luscan-Lumish Syndrome: Possible Involvement of Enhanced GH Signaling

Journal

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 106, Issue 3, Pages 718-723

Publisher

ENDOCRINE SOC
DOI: 10.1210/clinem/dgaa893

Keywords

overgrowth syndrome; growth hormone; gene mutation; gigantism; signaling

Funding

  1. Japan Society for the Promotion of Science (KAKENHI) [17K16164, 23659477, 26670459]
  2. Japan Agency for Medical Research and Development [17bm0804012h0001]
  3. Uehara Memorial Foundation
  4. Naito Foundation
  5. Grants-in-Aid for Scientific Research [17K16164] Funding Source: KAKEN

Ask authors/readers for more resources

Luscan-Lumish syndrome (LLS) is a rare genetic disorder characterized by abnormal height, obesity, and Chiari I malformation. A study identified a novel mutation in the SETD2 gene in a patient with LLS, suggesting aberrant GH signaling may play a role in the development of LLS.
Context: Luscan-Lumish syndrome (LLS) is characterized by postnatal overgrowth, obesity, Chiari I malformation, seizures, and intellectual disability. SET domain-containing protein 2 (SETD2) is a histone methyltransferase, where mutations in the gene are associated with the development of LLS. However, mechanisms underlying LLS remain unclear. Case Description: A 20-year-old man was referred to our hospital because of tall stature. His body height was 188.2 cm (+3.18 SD) and he showed obesity with a body mass index of 28.4 kg/m(2). He exhibited acral overgrowth, jaw malocclusion, and prognathism, but no history of seizures, intellectual disability, or speech delay. Serum growth hormone (GH), insulin-like growth factor 1 (IGF-1), and nadir GH levels after administration of 75 g oral glucose were within normal range. Pituitary magnetic resonance imaging showed no pituitary adenoma, but Chiari I malformation. Whole exome sequencing analysis of the proband revealed a de novo heterozygous germline mutation in SETD2 (c.236T>A, p.L79H). Skin fibroblasts derived from the patient grew faster than those from his father and the control subject. In addition, these cells showed enhanced tyrosine phosphorylation and transcriptional activity of signal transducer and activator of transcription 5b (STAT5b) and increased IGF-1 expression induced by GH. Conclusion: This is a mild case of LLS with a novel mutation in SETD2 without neurological symptoms. LLS should be differentiated in a patient with gigantism without pituitary tumors. Although further investigation is necessary, this is the first study to suggest the involvement of aberrant GH signaling in the development of LLS.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available